Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma

Journal of Experimental Medicine

Volumn 209, Issue 11, 2012, Pages 1985-2000

  Croci, Diego O ^a,b   Salatino, Mariana ^a,b   Rubinstein, Natalia ^b   Cerliani, Juan P ^a   Cavallin, Lucas E ^c   Leung, Howard J ^c   Ouyang, Jing ^d   Ilarregui, Juan M ^a,b   Toscano, Marta A ^a,b   Domaica, Carolina I ^a,b   Croci, María C ^e   Shipp, Margaret A ^d   Mesri, Enrique A ^c   Albini, Adriana ^f   Rabinovich, Gabriel A ^a,b,g  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^c UNIVERSITY OF MIAMI   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e UNIVERSIDAD NACIONAL DEL COMAHUE   (Argentina)

^f IRCCS MULTIMEDICA   (Italy)

^g UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1; GLYCAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MONOCLONAL ANTIBODY; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VIVO STUDY; KAPOSI SARCOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SPINDLE CELL; TUMOR REGRESSION;

ANIMALS; ANOXIA; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL HYPOXIA; CELL LINE, TUMOR; CELLS, CULTURED; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOBLOTTING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SARCOMA, KAPOSI; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870279245     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111665     Document Type: Article

References (63)

1. Albini, A., M. Morini, F. D'Agostini, N. Ferrari, F. Campelli, G. Arena, D.M. Noonan, C. Pesce, and S. De Flora. 2001. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 61:8171-8178.
2. Alcendor, D.J., S.M. Knobel, P. Desai, W.Q. Zhu, H.E. Vigil, and G.S. Hayward. 2010. KSHV downregulation of galectin-3 in Kaposi's sarcoma. Glycobiology. 20:521-532. http://dx.doi.org/10.1093/glycob/cwp204
3. Banh, A., J. Zhang, H. Cao, D.M. Bouley, S. Kwok, C. Kong, A.J. Giaccia, A.C. Koong, and Q.T. Le. 2011. Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res. 71:4423-4431. http://dx.doi.org/10.1158/0008-5472.CAN-10-4157
4. Casper, C. 2011. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu. Rev. Med. 62:157-170. http://dx.doi.org/10.1146/annurev-med-050409-103711
5. Cedeno-Laurent, F., R. Watanabe, J.E. Teague, T.S. Kupper, R.A. Clark, and C.J. Dimitroff. 2012. Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood. 119:3534-3538. http://dx.doi.org/10.1182/blood-2011-12-396457
6. Cesarman, E., E.A. Mesri, and M.C. Gershengorn. 2000. Viral G protein- coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J. Exp. Med. 191:417-422. http://dx.doi.org/10.1084/jem.191.3.417
7. Chaisuparat, R., J. Hu, B.C. Jham, Z.A. Knight, K.M. Shokat, and S. Montaner. 2008. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res. 68:8361-8368. http://dx.doi.org/10.1158/0008-5472.CAN-08-0878
8. Chan, D.A., T.L. Kawahara, P.D. Sutphin, H.Y. Chang, J.T. Chi, and A.J. Giaccia. 2009. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell. 15:527-538. http://dx.doi.org/10.1016/j.ccr.2009.04.010
9. Chung, A.S., and N. Ferrara. 2011. Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27:563-584. http://dx.doi.org/10.1146/annurev-cellbio-092910-154002
10. Cornelissen, M., A.C. van der Kuyl, R. van den Burg, F. Zorgdrager, C.J.M. van Noesel, and J. Goudsmit. 2003. Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer. 3:7. http://dx.doi.org/10.1186/1471-2407-3-7
11. Delgado, V.M.C., L.G. Nugnes, L.L. Colombo, M.F. Troncoso, M.M. Fernández, E.L. Malchiodi, I. Frahm, D.O. Croci, D. Compagno, G.A. Rabinovich, et al. 2011. Modulation of endothelial cell migration and angiogenesis: a novel function for the "tandem-repeat" lectin galectin-8. FASEB J. 25:242-254. http://dx.doi.org/10.1096/fj.09-144907
12. Favre, D., S. Lederer, B. Kanwar, Z.M. Ma, S. Proll, Z. Kasakow, J. Mold, L. Swainson, J.D. Barbour, C.R. Baskin, et al. 2009. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 5:e1000295. http://dx.doi.org/10.1371/journal.ppat.1000295
13. Fernández, G.C., J.M. Ilarregui, C.J. Rubel, M.A. Toscano, S.A. Gómez, M. Beigier Bompadre, M.A. Isturiz, G.A. Rabinovich, and M.S. Palermo. 2005. Galectin-3 and soluble fibrinogen act in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology. 15:519-527. http://dx.doi.org/10.1093/glycob/cwi026
14. kB pathway is required for inflammatory gene expression in response to hypoxia. J. Immunol. 186:1091-1096. http://dx.doi.org/10.4049/jimmunol.1002256
15. Fraisl, P., M. Mazzone, T. Schmidt, and P. Carmeliet. 2009. Regulation of angiogenesis by oxygen and metabolism. Dev. Cell. 16:167-179. http://dx.doi.org/10.1016/j.devcel.2009.01.003
16. Ganem, D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Invest. 120:939-949. http://dx.doi.org/10.1172/JCI40567
17. Haque, M., D.A. Davis, V. Wang, I. Widmer, and R. Yarchoan. 2003. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) contains hypoxia response elements: relevance to lytic induction by hypoxia. J. Virol. 77: 6761-6768. http://dx.doi.org/10.1128/JVI.77.12.6761-6768.2003
18. Hsieh, S.H., N.W. Ying, M.H. Wu, W.F. Chiang, C.L. Hsu, T.Y. Wong, Y.T. Jin, T.M. Hong, and Y.L. Chen. 2008. Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene. 27:3746-3753. http://dx.doi.org/10.1038/sj.onc.1211029
19. Ilarregui, J.M., D.O. Croci, G.A. Bianco, M.A. Toscano, M. Salatino, M.E. Vermeulen, J.R. Geffner, and G.A. Rabinovich. 2009. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10:981-991. http://dx.doi.org/10.1038/ni.1772
20. Ingrassia, L., I. Camby, F. Lefranc, V. Mathieu, P. Nshimyumukiza, F. Darro, and R. Kiss. 2006. Anti-galectin compounds as potential anticancer drugs. Curr. Med. Chem. 13:3513-3527. http://dx.doi.org/10.2174/092986706779026219
21. Ito, K., and S.J. Ralph. 2012. Inhibiting galectin-1 reduces murine lung metastasis with increased CD4(+) and CD8 (+) T cells and reduced cancer cell adherence. Clin. Exp. Metastasis. 29:561-572. http://dx.doi.org/10.1007/s10585-012-9471-7
22. Juszczynski, P., J. Ouyang, S. Monti, S.J. Rodig, K. Takeyama, J. Abramson, W. Chen, J.L. Kutok, G.A. Rabinovich, and M.A. Shipp. 2007. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl. Acad. Sci. USA. 104:13134-13139. http://dx.doi.org/10.1073/pnas.0706017104
23. Keith, B., R.S. Johnson, and M.C. Simon. 2012. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer. 12:9-22.
24. Kuo, P.L., J.Y. Hung, S.K. Huang, S.H. Chou, D.E. Cheng, Y.J. Jong, C.H. Hung, C.J. Yang, Y.M. Tsai, Y.L. Hsu, and M.S. Huang. 2011. Lung cancer-derived galectin-1 mediates dendritic cell anergy through inhibitor of DNA binding 3/IL-10 signaling pathway. J. Immunol. 186: 1521-1530. http://dx.doi.org/10.4049/jimmunol.1002940
25. Le, Q.T., G. Shi, H. Cao, D.W. Nelson, Y. Wang, E.Y. Chen, S. Zhao, C. Kong, D. Richardson, K.J. O'Byrne, et al. 2005. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J. Clin. Oncol. 23:8932-8941. http://dx.doi.org/10.1200/JCO.2005.02.0206
26. Liu, F.T., and G.A. Rabinovich. 2005. Galectins as modulators of tumour progression. Nat. Rev. Cancer. 5:29-41. http://dx.doi.org/10.1038/nrc1527
27. Ma, Q., L.E. Cavallin, B. Yan, S. Zhu, E.M. Duran, H. Wang, L.P. Hale, C. Dong, E. Cesarman, E.A. Mesri, and P.J. Goldschmidt-Clermont. 2009. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc. Natl. Acad. Sci. USA. 106:8683-8688. http://dx.doi.org/10.1073/pnas.0812688106
28. Ma, T., B.C. Jham, J. Hu, E.R. Friedman, J.R. Basile, A. Molinolo, A. Sodhi, and S. Montaner. 2010. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc. Natl. Acad. Sci. USA. 107:14363-14368. http://dx.doi.org/10.1073/pnas.1001065107
29. Markowska, A.I., F.T. Liu, and N. Panjwani. 2010. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 207:1981-1993. http://dx.doi.org/10.1084/jem.20090121
30. Markowska, A.I., K.C. Jefferies, and N. Panjwani. 2011. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J. Biol. Chem. 286:29913-29921. http://dx.doi.org/10.1074/jbc.M111.226423
31. Martin, D., R. Galisteo, Y. Ji, S. Montaner, and J.S. Gutkind. 2008. An NFkappaB gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene. 27:1844-1852. http://dx.doi.org/10.1038/sj.onc.1210817
32. Martin, D., R. Galisteo, A.A. Molinolo, R. Wetzker, E. Hirsch, and J.S. Gutkind. 2011. PI3Kγ mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell. 19:805-813. http://dx.doi.org/10.1016/j.ccr.2011.05.005
33. Mesri, E.A., E. Cesarman, and C. Boshoff. 2010. Kaposi's sarcoma and its associated herpesvirus. Nat. Rev. Cancer. 10:707-719. http://dx.doi.org/10.1038/nrc2888
34. Mizukami, Y., W.S. Jo, E.M. Duerr, M. Gala, J. Li, X. Zhang, M.A. Zimmer, O. Iliopoulos, L.R. Zukerberg, Y. Kohgo, et al. 2005. Induction of interleukin-8 preserves the angiogenic response in HIF-1α-deficient colon cancer cells. Nat. Med. 11:992-997.
35. Montaner, S., A. Sodhi, J.M. Servitja, A.K. Ramsdell, A. Barac, E.T. Sawai, and J.S. Gutkind. 2004. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood. 104:2903-2911. http://dx.doi.org/10.1182/blood-2003-12-4436
36. Montaner, S., A. Sodhi, A.K. Ramsdell, D. Martin, J. Hu, E.T. Sawai, and J.S. Gutkind. 2006. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res. 66:168-174. http://dx.doi.org/10.1158/0008-5472.CAN-05-1026
37. Mutlu, A.D., L.E. Cavallin, L. Vincent, C. Chiozzini, P. Eroles, E.M. Duran, Z. Asgari, A.T. Hooper, K.M. La Perle, C. Hilsher, et al. 2007. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell. 11:245-258. http://dx.doi.org/10.1016/j.ccr.2007.01.015
38. Myoung, J., and D. Ganem. 2011. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J. Virol. Methods. 174:12-21. http://dx.doi.org/10.1016/j.jviromet.2011.03.012
39. Nangia-Makker, P., Y. Honjo, R. Sarvis, S. Akahani, V. Hogan, K.J. Pienta, and A. Raz. 2000. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 156:899-909. http://dx.doi.org/10.1016/S0002-9440(10)64959-0
40. Norling, L.V., A.L. Sampaio, D. Cooper, and M. Perretti. 2008. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 22:682-690. http://dx.doi.org/10.1096/fj.07-9268com
41. Ouyang, J., P. Juszczynski, S.J. Rodig, M.R. Green, E. O'Donnell, T. Currie, M. Armant, K. Takeyama, S. Monti, G.A. Rabinovich, et al. 2011. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 117:4315-4322. http://dx.doi.org/10.1182/blood-2010-11-320481
42. Paulson, J.C., O. Blixt, and B.E. Collins. 2006. Sweet spots in functional glycomics. Nat. Chem. Biol. 2:238-248. http://dx.doi.org/10.1038/nchembio785
43. Paz, A., R. Haklai, G. Elad-Sfadia, E. Ballan, and Y. Kloog. 2001. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene. 20:7486-7493. http://dx.doi.org/10.1038/sj.onc.1204950
44. Rabinovich, G.A., and D.O. Croci. 2012. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity. 36: 322-335. http://dx.doi.org/10.1016/j.immuni.2012.03.004
45. Rabinovich, G.A., G. Daly, H. Dreja, H. Tailor, C.M. Riera, J. Hirabayashi, and Y. Chernajovsky. 1999. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J. Exp. Med. 190:385-398. http://dx.doi.org/10.1084/jem.190.3.385
46. Rabinovich, G.A., A. Cumashi, G.A. Bianco, D. Ciavardelli, I. Iurisci, M. D'Egidio, E. Piccolo, N. Tinari, N. Nifantiev, and S. Iacobelli. 2006. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology. 16:210-220. http://dx.doi.org/10.1093/glycob/cwj056
47. Rius, J., M. Guma, C. Schachtrup, K. Akassoglou, A.S. Zinkernagel, V. Nizet, R.S. Johnson, G.G. Haddad, and M. Karin. 2008. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature. 453:807-811. http://dx.doi.org/10.1038/nature06905
48. Rubinstein, N., M. Alvarez, N.W. Zwirner, M.A. Toscano, J.M. Ilarregui, A. Bravo, J. Mordoh, L. Fainboim, O.L. Podhajcer, and G.A. Rabinovich. 2004. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell. 5:241-251. http://dx.doi.org/10.1016/S1535-6108(04)00024-8
49. Salomonsson, E., V.L. Thijssen, A.W. Griffioen, U.J. Nilsson, and H. Leffler. 2011. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J. Biol. Chem. 286:13801-13804. http://dx.doi.org/10.1074/jbc.C111.229096
50. St-Pierre, C., H. Manya, M. Ouellet, G.F. Clark, T. Endo, M.J. Tremblay, and S. Sato. 2011. Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4. J. Virol. 85:11742-11751. http://dx.doi.org/10.1128/JVI.05351-11
51. Sun, Q., H. Matta, G. Lu, and P.M. Chaudhary. 2006. Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappaB activation. Oncogene. 25:2717-2726. http://dx.doi.org/10.1038/sj.onc.1209298
52. Tang, D., Z. Yuan, X. Xue, Z. Lu, Y. Zhang, H. Wang, M. Chen, Y. An, J. Wei, Y. Zhu, et al. 2012. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int. J. Cancer. 130:2337-2348. http://dx.doi.org/10.1002/ijc.26290
53. Thijssen, V.L., R. Postel, R.J. Brandwijk, R.P. Dings, I. Nesmelova, S. Satijn, N. Verhofstad, Y. Nakabeppu, L.G. Baum, J. Bakkers, et al. 2006. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. USA. 103:15975-15980. http://dx.doi.org/10.1073/pnas.0603883103
54. Thijssen, V.L., B. Barkan, H. Shoji, I.M. Aries, V. Mathieu, L. Deltour, T.M. Hackeng, R. Kiss, Y. Kloog, F. Poirier, and A.W. Griffioen. 2010. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 70:6216-6224. http://dx.doi.org/10.1158/0008-5472.CAN-09-4150
55. Toscano, M.A., G.A. Bianco, J.M. Ilarregui, D.O. Croci, J. Correale, J.D. Hernandez, N.W. Zwirner, F. Poirier, E.M. Riley, L.G. Baum, and G.A. Rabinovich. 2007. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8:825-834. http://dx.doi.org/10.1038/ni1482
56. kB controls expression of the immunoregulatory glycan-binding protein galectin-1. Mol. Immunol. 48:1940-1949. http://dx.doi.org/10.1016/j.molimm.2011.05.021
57. Tsuboi, S., M. Sutoh, S. Hatakeyama, N. Hiraoka, T. Habuchi, Y. Horikawa, Y. Hashimoto, T. Yoneyama, K. Mori, T. Koie, et al. 2011. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J. 30:3173-3185. http://dx.doi.org/10.1038/emboj.2011.215
58. Vieira, J., and P.M. O'Hearn. 2004. Use of the red fluorescent protein as a marker of Kaposi's sarcoma-associated herpesvirus lytic gene expression. Virology. 325:225-240. http://dx.doi.org/10.1016/j.virol.2004.03.049
59. Wang, H.W., M.W. Trotter, D. Lagos, D. Bourboulia, S. Henderson, T. Mäkinen, S. Elliman, A.M. Flanagan, K. Alitalo, and C. Boshoff. 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet. 36:687-693. http://dx.doi.org/10.1038/ng1384
60. Wu, F.Y., Q.Q. Tang, H. Chen, C. ApRhys, C. Farrell, J. Chen, M. Fujimuro, M.D. Lane, and G.S. Hayward. 2002. Lytic replication-associated protein (RAP) encoded by Kaposi sarcoma-associated herpesvirus causes p21CIP-1-mediated G1 cell cycle arrest through CCAAT/enhancer-binding protein-α. Proc. Natl. Acad. Sci. USA. 99:10683-10688. http://dx.doi.org/10.1073/pnas.162352299
61. Ye, F., F. Zhou, R.G. Bedolla, T. Jones, X. Lei, T. Kang, M. Guadalupe, and S.J. Gao. 2011. Reactive oxygen species hydrogen peroxide mediates Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathog. 7:e1002054. http://dx.doi.org/10.1371/journal.ppat.1002054
62. Zhao, X.Y., T.T. Chen, L. Xia, M. Guo, Y. Xu, F. Yue, Y. Jiang, G.Q. Chen, and K.W. Zhao. 2010. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis. 31:1367-1375. http://dx.doi.org/10.1093/carcin/bgq116
63. Zhao, X.Y., K.W. Zhao, Y. Jiang, M. Zhao, and G.Q. Chen. 2011. Synergistic induction of galectin-1 by CCAAT/enhancer binding protein α and hypoxia-inducible factor 1α and its role in differentiation of acute myeloid leukemic cells. J. Biol. Chem. 286:36808-36819. http://dx.doi.org/10.1074/jbc.M111.247262